文献速递类风湿关节炎

简报:抗人类T淋巴细胞病毒I型抗体阳性类风湿关节炎患者中肿瘤坏死因子抑制剂疗效减弱

Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2018-05-25

在日本西南部HTLV-I感染流行区开展观察性研究,585例新启用TNF抑制剂作为首个生物制剂的RA患者中50例(8.5%)抗HTLV-I抗体阳性。抗HTLV-I抗体阴性患者EULAR缓解率显著更优(P=0.0277),多因素回归显示抗体状态与EULAR缓解率及DAS28-ESR变化显著相关,在ACPA阴性者中尤为突出。24周治疗期间无ATL或HAM发生,但长期风险未知。

要点

  • 抗HTLV-I抗体阳性RA患者TNF抑制剂疗效可能减弱,EULAR缓解率显著低于抗体阴性者(P=0.0277)。
  • 抗HTLV-I抗体状态与EULAR缓解率及DAS28-ESR变化显著相关,ACPA阴性者中尤为突出。
  • 24周TNF抑制剂治疗期间无ATL或HAM发生,但长期风险未知。

核心结论

  • 抗HTLV-I抗体阳性RA患者中TNF抑制剂疗效可能减弱。
  • 24周使用TNF抑制剂期间未发生ATL或HAM,但长期风险未知。

研究设计与样本

  • 在日本西南部HTLV-I感染流行区开展观察性研究,纳入585例新启用TNF抑制剂作为首个生物制剂改善病情抗风湿药的RA患者。

主要发现

  • 50例(8.5%)抗HTLV-I抗体阳性,该组入组时年龄显著高于抗HTLV-I抗体阴性患者(n=535)。
  • 全部患者中位DAS28-ESR为5.21,82%为ACPA阳性,TNF抑制剂24周持续率为89%。
  • 两组中位DAS28-ESR在24周均显著下降,抗HTLV-I抗体阴性患者EULAR缓解率显著更优(P=0.0277)。
  • 多因素回归分析显示抗HTLV-I抗体状态与EULAR缓解率及DAS28-ESR变化显著相关,在ACPA阴性者中尤为突出。
  • 24周治疗期间无患者发生ATL或HAM。

关键数值与推荐

  • 抗HTLV-I抗体阳性50例(8.5%),抗HTLV-I抗体阴性535例。
  • 全部患者中位DAS28-ESR为5.21,82%为ACPA阳性。
  • TNF抑制剂24周持续率为89%。
  • 抗HTLV-I抗体阴性患者EULAR缓解率显著优于抗体阳性患者(P=0.0277)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出TNF抑制剂使用24周时未发生ATL或HAM,但长期风险未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of tumor necrosis factor (TNF) inhibitors for the treatment of human T lymphotropic virus type I (HTLV-I)-positive patients with rheumatoid arthritis (RA) in an area endemic for HTLV-I infection. METHODS: We conducted an observational study of 585 RA patients in whom TNF inhibitors were newly introduced as a first biologic disease-modifying antirheumatic drug in an area in southwestern Japan that is endemic for HTLV-I infection. RESULTS: Fifty patients (8.5%) were anti-HTLV-I antibody-positive. The ages of the patients in this group were significantly higher at entry compared with the ages of patients who were anti-HTLV-I antibody-negative (n = 535). The median Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) was 5.21. Among the total group of patients, 82% were anti-citrullinated protein antibody (ACPA)-positive. The persistence rate of TNF inhibitors at 24 weeks was 89%. The median DAS28-ESR was significantly decreased at 24 weeks in each group. The European League Against Rheumatism (EULAR) response rate was significantly better in the anti-HTLV-I antibody-negative patients (P = 0.0277). Multiple regression analysis demonstrated that anti-HTLV-I antibody status was significantly associated with the EULAR response rate and change in the DAS28-ESR and was prominent especially in the ACPA-negative subjects. No patients developed adult T cell leukemia/lymphoma (ATL) or HTLV-I-associated myelopathy (HAM) during the 24-week treatment period. CONCLUSION: The efficacy of TNF inhibitors may be attenuated in anti-HTLV-I antibody-positive patients with RA. ATL and HAM did not develop when TNF inhibitors were used for 24 weeks, but the long-term risk is not known.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Suzuki T, Fukui S, Umekita K, et al. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis. Arthritis Rheumatol. 2018. PMID: 29471588. doi:10.1002/art.40461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。